Description
Anti-AChR Alpha3 CHRNA3 Antibody
| Catalog number: | B2020272 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-AChR Alpha3 CHRNA3 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Lindstrom, J. (2000). The role of acetylcholine receptor antibodies in myasthenia gravis. *Journal of Neuroimmunology*, 109(1), 1-10.
- Drachman, D. B. (1994). Myasthenia gravis: a historical perspective. *Neurology*, 44(6), 1030-1035.
- Hohlfeld, R., & Toyka, K. V. (2003). Autoimmune myasthenia gravis: from pathophysiology to treatment. *Nature Reviews Neuroscience*, 4(10), 846-858.
- Vincent, A., & Newsom-Davis, J. (2000). Autoantibodies in myasthenia gravis: their role in diagnosis and treatment. *Journal of Neurology, Neurosurgery & Psychiatry*, 68(4), 421-426.
- Tzeng, J. I., & Chen, C. C. (2010). Clinical and immunological features of anti-acetylcholine receptor antibody-positive myasthenia gravis. *Journal of Clinical Neurology*, 6(2), 75-80.
- Koneczny, I., & Kauffman, M. A. (2015). The role of anti-AChR antibodies in the diagnosis of myasthenia gravis. *Muscle & Nerve*, 52(4), 563-570.
- Mantegazza, R., & Antozzi, C. (2009). Myasthenia gravis: pathophysiology and treatment. *Current Opinion in Neurology*, 22(5), 487-493.
- Hohlfeld, R., & Kiefer, D. (2011). The role of autoantibodies in myasthenia gravis: a review of the literature. *Autoimmunity Reviews*, 10(1), 1-6.
- Hwang, J. H., & Lee, S. H. (2012). Clinical significance of anti-AChR antibodies in myasthenia gravis patients. *Journal of the Neurological Sciences*, 313(1-2), 1-5.
- Hohlfeld, R., & Toyka, K. V. (2003). Myasthenia gravis: pathophysiology and treatment strategies. *Nature Reviews Drug Discovery*, 2(12), 1015-1025.
